In our global healthcare weekly, we focus on identifiying key stock catalysts for biotech companies in the fourth quarter this week.

Corcept Therapeutics Incorporated (NASDAQ: CORT) is pharmaceutical company focusing on the discovery, development, and commercialization of drugs that modulate cortisol activity. With a market capitalization of US$5.1 billion and an estimated cash balance of US$523.5 million, Corcept is best known for Korlym (mifepristone), an FDA-approved treatment for Cushing’s syndrome. The firm’s pipeline includes relacorilant, a key investigational drug designed to treat Cushing’s syndrome, which is caused by a benign adrenal tumor. This second Phase 3 trial, known as GRADIENT, has completed enrollment with 137 patients randomized to receive relacorilant or placebo for 22 weeks. The primary endpoints of the trial are improvements in hypertension and glucose control.